We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




High-Sensitivity C-Reactive Protein Investigated in Acute Myocardial Infarction Patients

By LabMedica International staff writers
Posted on 12 Nov 2020
Type 2 diabetes mellitus (DM) is a common comorbidity in acute myocardial infarction (AMI), and it is associated with two-fold higher in-hospital and long-term mortality rates and with a higher risk of recurrent cardiovascular events.

C-reactive protein (CRP), an acute phase protein secreted by the liver, is the most widely used biomarker for detecting inflammatory conditions. More...
To assess cardiovascular risk, physicians have now adopted high-sensitivity CRP (hs-CRP), instead of standard CRP assays that monitor infections and other inflammatory conditions.

Cardiologists at the Monzino Cardiological Center Institute (Milan, Italy) carried out a prospective, observational study and enrolled 2,178 patients with AMI between June 1, 2012 and October 1, 2017. Patients were considered as suffering from DM if one of the following conditions were present: personal history of DM reported in clinical record, treatment with glucose lowering drugs, or a glycated hemoglobin value ≥ 6.5% (48 mmol/mol). High-sensitivity-CRP was measured at hospital admission by Cobas assay (particle-enhanced immunoturbidimetric assay) on Cobas c501 (Roche Diagnostics, Risch-Rotkreuz, Switzerland). A hs-CRP value ≥ 2 mg/L was considered a sign of inflammation.

The scientists reported that 548 (26%) patients had DM and they had higher hs-CRP levels than non-DM patients (5.32 versus 3.24 mg/L)). The primary endpoint incidence in the overall population (7%, 9%, 13%, 22%), in DM (14%, 9%, 21%, 27%), and non-DM (5%, 8%, 10%, 19%) patients increased in parallel with hs-CRP quartiles. The adjusted risk of the primary endpoint increased in parallel with hs-CRP quartiles in DM and non-DM patients, but this relationship was less evident in DM patients.

In the overall population, the adjusted odds ratio (OR) of the primary endpoint associated with an hs-CRP value ≥ 2 mg/L was 2.10. For the same risk, hs-CRP was 7 mg/L and 2 mg/L in patients with and without DM. A similar behavior was observed for the secondary endpoint when the hazard ratio (HR) associated with an hs-CRP value ≥ 2 mg/L found in the overall population was 2.25. For the same risk, hs-CRP was 8 mg/L and 1.5 mg/L in DM and non-DM patients.

The authors concluded that hs-CRP predicts in-hospital outcome and two-year mortality in AMI patients with and without DM. However, in DM patients, the same risk of developing events as in non-DM patients is associated to higher hs-CRP levels. The study was published on October 20, 2020 in the journal Cardiovascular Diabetology.



New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
ESR Analyzer
TEST1 2.0
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.